Director sold ~$608K of Roivant Sciences
Scheduled in advanceLoading…
Roivant Sciences
ROIV · NASDAQ · Biotechnology
ROIV · NASDAQ · Biotechnology
Biotechnology company based in London, United Kingdom.
In the last 90 days, no insider of Roivant Sciences reported an open-market purchase and 18 open-market sales worth about $59.8M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$35.78
Last 12 months
Not enough history
Market value
$25.8B
Revenue
$1.44M
−33.5% vs the same quarter a year earlier
Free cash flow, last 12 months
−$821M
This quarter −$271M, a year earlier −$208M
Net debt
—
Debt —, cash $1.25B, at Jun 30, 2026
Net income, last 12 months
−$266M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
18 sales
$59.8M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2026
$8.26M
−71.6% vs the year before
Net income, fiscal 2026
−$300M
A loss for the year
Shares outstanding
722M
As of Jul 31, 2026
In fiscal 2025 the company spent $1.29B buying back its own shares. Cash actually paid, from its cash-flow statement.
Director sold ~$608K of Roivant Sciences
Scheduled in advanceDirector sold ~$33K of Roivant Sciences
Scheduled in advanceCEO sold ~$7.32M of Roivant Sciences
Scheduled in advanceDirector sold ~$172K of Roivant Sciences
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $16.26 on Oct 6, 2025 to $35.78 on Oct 5, 2026 (+120.0%). Disclosed activity in the last 12 months: 0 insider purchases, 122 insider sales (36 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.